Pender Alexandra, Popat Sanjay
Department of Medicine, Royal Marsden Hospital, London, UK and Division of Molecular Pathology, Institute of Cancer Research, London, UK.
Department of Medicine, Royal Marsden Hospital, Fulham Road, London, SW3 6JJ
Ther Adv Respir Dis. 2015 Jun;9(3):97-104. doi: 10.1177/1753465815577738. Epub 2015 Mar 22.
Molecular profiling of nonsmall cell lung cancer (NSCLC) contributes to better understanding the different molecular subtypes of this heterogeneous group of diseases. The discovery of oncogenic ALK rearrangements in NSCLC and the subsequent success in their therapeutic targeting with crizotinib reinforces the benefits of a precision approach to systemic anticancer therapy. In addition, the rapid development of crizotinib from first discovery thorough accelerated US Food and Drug Administration approval, and late stage confirmatory clinical trials, exemplifies the success of the drug development strategy of close collaboration between clinicians, industry and regulatory authorities. In this review we describe the identification of ALK rearranged NSCLC, clinical characteristics of such patients, and clinical outcomes when treated with crizotinib.
非小细胞肺癌（NSCLC）的分子谱分析有助于更好地理解这一异质性疾病群体的不同分子亚型。NSCLC中致癌性ALK重排的发现以及随后使用克唑替尼对其进行靶向治疗的成功，强化了精准全身抗癌治疗方法的益处。此外，克唑替尼从首次发现到美国食品药品监督管理局加速批准以及后期确证性临床试验的快速发展，例证了临床医生、产业界和监管机构密切合作的药物开发策略的成功。在本综述中，我们描述了ALK重排NSCLC的识别、此类患者的临床特征以及使用克唑替尼治疗时的临床结果。
